Celgene Wants Mylan Sanctioned For Bid To Add Witnesses
By Bill Wichert ( December 18, 2018, 9:48 PM EST) -- Celgene Corp. urged a New Jersey federal judge Tuesday to reject Mylan Pharmaceuticals Inc.'s bid to add three consumer witnesses in its antitrust case against Celgene over cancer drugs Thalomid and Revlimid, or at least sanction Mylan through attorneys' fees and costs in connection with additional discovery related to the witnesses....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.